SEC Form 15-12G filed by Calithera Biosciences Inc.

$CALA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CALA alert in real time by email
15-12G 1 d481555d1512g.htm 15-12G 15-12G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR

SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-36644

 

 

Calithera Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

343 Oyster Point Blvd., Suite 200

South San Francisco, California 94080

(650) 870-1000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.0001 par value

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

 

Rule 12g-4(a)(2)

 

Rule 12h-3(b)(1)(i)

 

Rule 12h-3(b)(1)(ii)

 

Rule 15d-6

 

Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date: 13.

Pursuant to the requirements of the Securities Exchange Act of 1934, Calithera Biosciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: March 14, 2023     By:   /S/ SUSAN M. MOLINEAUX, PH.D.
    Name:   Susan M. Molineaux, Ph.D.
    Title:   President and Chief Executive Officer

 

 

 

Get the next $CALA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CALA

DatePrice TargetRatingAnalyst
1/31/2022$4.00Buy
Ladenburg Thalmann
1/20/2022$1.00 → $3.00Market Perform → Outperform
SVB Leerink
11/8/2021Buy → Neutral
HC Wainwright & Co.
11/5/2021Outperform → Market Perform
William Blair
More analyst ratings

$CALA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

    SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: "CALA"). Calithera Biosciences, Inc. (the "Company") announced that it was unable to achieve a quorum of stockholders at its special meeting of stockholders scheduled to be held on June 29, 2023 (the "Special Meeting"), for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution. In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations. After consulting with its proxy solicitation advisors, the Company concluded that further attempts to solicit proxies for the Special Meeting would in all likelihoo

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

    SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC:CALA) (the "Company") announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the "Special Meeting"),  for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution (the "Plan of Dissolution").  In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations.   The Company continues to expect that its existing capital resources together with the net proceeds from the sale of its assets will enable it to meet its remaining liabilities and obligations with sufficient reser

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company's operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter. "The Board of Directors and management devoted substantial t

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CALA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CALA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CALA
SEC Filings

See more

$CALA
Leadership Updates

Live Leadership Updates

See more
  • Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 50,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on December 31, 2020. One-fourth of the option vests in December 2021, and the balance of the option vests in a series of thirty-six successive equ

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CALA
Financials

Live finance-specific insights

See more
  • Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. "Earlier in the fourth quarter, we were very pleased to announce that we received FDA Fast Track designation for sapanisertib. This designation facilitates more frequent communication with the Agency, as well as a number of other benefits that could support our efforts to bring sapanisertib to patients in this area of high unmet need more quickly," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "Today we a

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants who wish to join the conference call by telephone can use this link to register and receive the dial-in numbers and unique PIN to access the call. The conference call registration and live audio webcast c

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022. "We continue to deliver on our commitment to efficiently advance our clinical programs, successfully initiating two new clinical trials and sharing program updates at two important medical conferences," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "We look forward to sharing data from the ongoing mivavotinib and sapanisertib phase 2 trials by the first quarter of 2023, as well as providing an update on the p

    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CALA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more